These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8664028)

  • 1. High-dose chemotherapy for breast cancer.
    Leonard RC
    Eur J Cancer; 1996 Feb; 32A(2):205-8. PubMed ID: 8664028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of dose and schedule in cancer chemotherapy: breast cancer.
    Leonard RC
    Anticancer Drugs; 1995 Oct; 6 Suppl 5():17-27. PubMed ID: 8845492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
    Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
    J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy in breast cancer.
    Lake DE; Hudis CA
    Drugs; 2004; 64(17):1851-60. PubMed ID: 15329034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Studies with high-dose chemotherapy and subsequent autologous stem cell transplantation in breast carcinoma].
    Nitz U; Adomeit A; Mohrmann S; Fossari A; Frick M
    Praxis (Bern 1994); 1998 Apr; 87(17):578-83. PubMed ID: 9623324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metastatic breast cancer: what are the objectives?].
    Salvini P; Ripa C; Ginanni V
    Tumori; 2000; 86(5 Suppl 1):S22-8. PubMed ID: 11195289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [High dose chemotherapy in treatment of breast carcinoma: current status and limits of this method of therapy].
    Derigs HG; Huber C; Mahlke M; Kolbe K
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):190-7. PubMed ID: 8682284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of high-dose chemotherapy in solid tumours.
    Nieboer P; de Vries EG; Mulder NH; van der Graaf WT
    Cancer Treat Rev; 2005 May; 31(3):210-25. PubMed ID: 15944050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.
    Hudis C; Fornier M; Riccio L; Lebwohl D; Crown J; Gilewski T; Surbone A; Currie V; Seidman A; Reichman B; Moynahan M; Raptis G; Sklarin N; Theodoulou M; Weiselberg L; Salvaggio R; Panageas KS; Yao TJ; Norton L
    J Clin Oncol; 1999 Apr; 17(4):1118. PubMed ID: 10561169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
    Kasimir-Bauer S; Mayer S; Bojko P; Borquez D; Neumann R; Seeber S
    Clin Cancer Res; 2001 Jun; 7(6):1582-9. PubMed ID: 11410494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
    Schulman KA; Stadtmauer EA; Reed SD; Glick HA; Goldstein LJ; Pines JM; Jackman JA; Suzuki S; Styler MJ; Crilley PA; Klumpp TR; Mangan KF; Glick JH
    Bone Marrow Transplant; 2003 Feb; 31(3):205-10. PubMed ID: 12621482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective construction and validation of a prognostic score to identify patients who benefit from third-line chemotherapy for metastatic breast cancer in terms of overall survival: the METAL3 Study.
    Filleron T; Bonnetain F; Mancini J; Martinez A; Roché H; Dalenc F
    Contemp Clin Trials; 2015 Jan; 40():1-8. PubMed ID: 25460338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow.
    Brockstein BE; Williams SF
    Stem Cells; 1996 Jan; 14(1):79-89. PubMed ID: 8820954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in systemic chemotherapy of primary breast cancer: an overview.
    Hortobagyi GN
    J Natl Cancer Inst Monogr; 2001; (30):72-9. PubMed ID: 11773296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.